PointClickCare vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud-based EHR and care coordination platform for long-term and post-acute care organizations. Mississauga, Canada. Raised $172M+, unicorn. Serves 27,000+ care facilities across North America.
About
PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the company has raised over $172 million and achieved unicorn valuation status. PointClickCare serves over 27,000 care facilities including skilled nursing facilities, senior living communities, assisted living centers, and home health agencies across the United States and Canada. The platform provides electronic health records (EHR), billing, care coordination, and business intelligence capabilities.\n\nPointClickCare's platform is built around the complex clinical and regulatory workflows unique to post-acute care, which differ substantially from acute hospital EHR requirements. The system manages MDS assessments, care planning, medication administration records, therapy documentation, and the complex billing requirements for Medicare, Medicaid, and managed care payers. Its network effect is significant — because PointClickCare connects so many facilities, care transitions between hospitals and post-acute settings can be managed with streamlined data exchange.\n\nThe company has expanded through strategic acquisitions including Collective Medical, which added care transition and high-risk patient identification capabilities powered by a large hospital and payer data network. PointClickCare's Marketplace ecosystem allows third-party technology vendors to integrate with the platform, creating an app store model that extends its functionality without requiring PointClickCare to build every adjacent capability. As value-based care models push accountable care organizations to manage patient outcomes across the full episode of care, PointClickCare's position at the post-acute node of the care continuum becomes increasingly strategically important.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.